Rhythm Pharmaceuticals Stock News

Lantheus LNTH +34%. Evolent Health (EVH) +18%. Orphazyme (ORPH) -36%. Rhythm Pharmaceuticals RYTM -24%.

Rhythm Pharmaceuticals (RYTM) is trading ~8% lower in the pre-market Thursday after the commercial-stage biopharma company announced that the U.S

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA --

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, March 1, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare geneti

Rhythm Pharmaceuticals <> has recorded the biggest intraday gain since November 2020 after Ladenburg Thalmann upgraded the commercial-stage biopharmaceutical company to Buy…

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE: EQNR ) from Hold to Buy. For the fourth quarter, Equinor had an EPS of $1.35, compared to year-ago quarter EPS of $0.17. The current stock performance of Equinor shows a 52-week-high of $32.16 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $29.45. Argus Research upgraded the previous rating for Canadian National Railway Co (NYSE: CNI ) from Hold to Buy. For the fourth quarter, Canadian National Railway had an EPS of $1.36, compared to year-ago quarter EPS of $1.10. The current stock performance of Canadian National Railway shows a 52-week-high of $136.22 and a 52-week-low of $100.66. Moreover, at the end of the last trading period, the closing price was at $126.93. According to TD Securities, the prior rating for Equinix Inc (NASDAQ: EQIX ) was changed from Hold to Buy. For the fourth quarter, Equinix had an EPS of $6.22, compared to year-ago quarter EPS of $5.76. At the moment, the stock has a 52-week-high of $885.26 and a 52-week-low of $586.73.

RYTM has a label expansion for its lead molecule. The molecule is approved in another indication for over a year.

Rhythm Pharmaceuticals <> announces the first patient has been dosed with setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, in Phase 2 DAYBREAK clinical trial

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News .

Wall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, []

Wells Fargo & Company initiated coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) in a report issued on Wednesday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the stock. Morgan Stanley lowered shares of Rhythm Pharmaceuticals from []

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have received a consensus recommendation of Hold from the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 [] The post Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from Brokerages appeared first on ETF Daily News .